Clinical Trial for the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
Latest Information Update: 04 Aug 2023
At a glance
- Drugs Anti-CD19 and anti-BCMA CART cell therapy-Yake Biotechnology (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 09 Sep 2021 New trial record